These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 27926517)

  • 1. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
    Huang L; Sowa Y; Sakai T; Pardee AB
    Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
    Huang L; Pardee AB
    Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
    Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
    Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
    Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
    Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
    Zhou W; Feng X; Han Han ; Guo S; Wang G
    Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
    Gillenwater AM; Zhong M; Lotan R
    Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.